Following on from information provided to NICE by the company in August 2022, the appraisal of Pembrolizumab with docetaxel for treating hormone-relapsed metastatic prostate cancer untreated with chemotherapy [ID3801] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Decision Selected
Process TA
ID number 3801

Timeline

Key events during the development of the guidance:

Date Update
31 August 2023 Discontinued. Following on from information provided to NICE by the company in August 2022, the appraisal of Pembrolizumab with docetaxel for treating hormone-relapsed metastatic prostate cancer untreated with chemotherapy [ID3801] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
23 August 2022 Suspended. As you will be aware the Department for Health & Social Care has asked NICE to carry out an appraisal of Pembrolizumab with docetaxel for treating hormone-relapsed metastatic prostate cancer untreated with chemotherapy [ID3801]. For information, the company have announced that MK-3475-921/KEYNOTE-921 did not meet its primary endpoints and therefore they will no longer be pursuing a Marketing Authorisation Application in this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties as and when the situation changes.
16 June 2021 Timelines for this appraisal are to be confirmed. Further information regarding the scheduling of this appraisal will be available in due course.

For further information on our processes and methods, please see our CHTE processes and methods manual